Assobiotec, percorso al 2036 per trasformare la ricerca in industria
Quattro priorità: formazione, trasferimento tecnologico, ricerca e semplificazione. Il ministro Urso: il settore è tra quelli che nella Ue investe di più e genera più valore aggiunto. Greco: «Creare le condizioni affinché le idee possano trasformarsi in prodotti e innovazione»
Assobiotec, a member organization of Federchimica, is focusing on four key areas - formation, research, technology transfer, and simplification - to transform biotech research into industry by 2036. This initiative, known as "Orizzonte Biotech 2036," aims to turn innovation and research into production. Federchimica president Fabrizio Greco emphasized that this is not an association plan but a shared responsibility of a country aspiring to be a leader in its future.
Assobiotec celebrated its 40th anniversary yesterday at the Ministry of Enterprises and Made in Italy in Rome, highlighting the growth of an expanding ecosystem with a strong international presence. In 2024, the Italian biotech system comprised around 6,000 enterprises with €53.4 billion in revenue and over 102,000 jobs, marking a 5% increase in revenue, 5% in employment, and 4% in growth compared to the previous year.
The Italian biotech landscape is characterized by a strong international projection. According to a recent "Report on Commercial Exchange of the Life Sciences Sector" by the Ministry of Enterprises and Made in Italy, exports in biotech health components grew significantly from €8.5 billion in 2021 to €22 billion in 2025. Imports also increased, from €10.1 billion to €18.1 billion.
Minister Adolfo Urso highlighted the importance of the pharma and biotech industry in Italy's industrial policy, noting that biotech is among the most productive sectors generating the most value-added and investing heavily in research and development. The European 'Biotech Act' is being developed to support biotech enterprises in research and investment, promoting better AI usage in drug development.
Italy's contribution lies in representing its needs in a high-growth sector to the European stage. The 'Made in Italy 2030' document identifies biotech and health as key areas of satisfaction. A long-term, medium-lung view is often missing, which Greco calls the "Biotech Journey," encompassing formation, research, development, transfer, and production to market.
The journey starts with a document titled "The Cracks of the System - The Framework, Challenges, and Prospects," followed by a report in December 2026 in collaboration with Politecnico di Milano. In 2027, a stakeholder discussion will take place.
Written by urgent.news from Il Sole 24 Ore's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.